Table 2.

Clinical and serologic data for the SLE patients in each ancestral background.

	African-American			European			Asian
	No	Yes	Total	No	Yes	Total	No	Yes	Total
Renal	0.53	0.47	507	0.72	0.28	1069	0.54	0.46	674
Malar rash	0.63	0.37	508	0.44	0.56	1068	0.56	0.44	674
Discoid rash	0.76	0.24	508	0.89	0.11	1069	0.92	0.08	674
Photosensitivity	0.63	0.37	507	0.34	0.66	1069	0.66	0.34	674
Arthritis	0.24	0.76	508	0.18	0.82	1069	0.38	0.62	674
Oral ulcers	0.76	0.24	508	0.53	0.47	1069	0.62	0.38	674
Serositis	0.48	0.52	448	0.57	0.43	1025	0.72	0.28	673
Neurologic	0.87	0.13	508	0.89	0.11	1069	0.93	0.07	674
Hematologic	0.28	0.72	508	0.39	0.61	778	0.15	0.85	674
Immunologic	0.13	0.87	505	0.26	0.74	1064	0.00	1.00	674
ANA	0.01	0.99	508	0.03	0.97	1069	0.00	1.00	674
Anti-Ro	0.71	0.29	475	0.80	0.20	655	0.66	0.34	659
Anti-La	0.91	0.09	475	0.92	0.08	661	0.92	0.08	659
Anti-Sm	0.84	0.16	384	0.98	0.02	586	0.90	0.10	40
Anti-nRNP	0.62	0.38	384	0.92	0.08	586	0.65	0.35	40
Anti-Ribosomal P	0.98	0.02	384	0.99	0.01	586	0.95	0.05	40

“No” indicates the proportion of subjects lacking the clinical feature, and “Yes” is the proportion of subjects in whom that feature is present. Total indicates the total number of subjects for whom data is available. The first 11 rows are parameters assessed according to the American College of Rheumatology criteria for SLE [2], while the five rows which begin with “Anti-” indicate particular SLE-associated autoantibody specificities. ANA: anti-nuclear antibody.